[144] Apellis Pharmaceuticals, Inc. SEC Filing
Rhea-AI Filing Summary
Apellis Pharmaceuticals insider Cedric Francois has filed a Form 144 to potentially sell 8,182 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $161,945.51 based on the figures in the notice. The stock was acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation.
The notice also reports that during the past three months, Francois sold 10,186 shares of common stock on 01/13/2026 for gross proceeds of $225,998.82. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Positive
- None.
Negative
- None.
Insights
Routine Form 144 filing discloses planned sale of recently vested shares.
This filing shows Cedric Francois has notified of an intent to sell up to 8,182 shares of Apellis Pharmaceuticals common stock. The shares were acquired on
The disclosure also lists a prior sale during the last three months: 10,186 common shares sold on